Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the ...

Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology Kidney Week 2024 ...

Penelope Oliver, a volunteer with Students Demand Action in California, talks to Hal about state laws involving firearms.

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...